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Measuring the overall genetic component of nevirapine
pharmacokinetics and the role of selected polymorphisms:
towards addressing the missing heritability in
pharmacogenetic phenotypes?
Janine E. Michelia, Leslie W. Chinna, Sarah B. Shugartsa, Ashish Patela,
Jeffrey N. Martinb,c, David R. Bangsberge and Deanna L. Kroetza,d
Objective Nevirapine is an important component of
highly active antiretroviral therapy used in the treatment
of HIV infection. There is a considerable variation in the
pharmacokinetics of nevirapine and this variation can
impact the efficacy and toxicity of nevirapine. Although
some of this variation can be attributed to environmental
factors, the degree to which heritability influences
nevirapine pharmacokinetics is unknown. This study
aims to estimate how much variation in nevirapine
pharmacokinetics is due to genetic factors and to
investigate the contribution of selected polymorphisms
to this variability.
Methods Two doses of immediate-release nevirapine
were administered to European (n=11) and African
American (n=6) participants recruited from the Research
in Access to Care in the Homeless cohort. A repeated drug
administration method was then used to determine the
relative genetic contribution (rGC) to variability in nevirapine
AUC0–6 h. Nevirapine plasma levels were quantified using
LC/MS/MS. Patients were also genotyped for selected
polymorphisms in candidate genes that may influence
nevirapine pharmacokinetics.
Results A significant rGC for nevirapine AUC0–6 h was
found in Europeans (P=0.02) and African Americans
(P=0.01). A trend toward higher nevirapine AUC0–6 h for
the CYP2B6 516TT (rs3745274; Q172H) genotype was
observed in European Americans (P=0.19).
Conclusion This study demonstrates that there is a
significant genetic component to variability in nevirapine
pharmacokinetics. Although genetic variants such
as CYP2B6 polymorphisms attributed to some of
this variation, these data suggest that there may be
additional genetic factors that influence nevirapine
pharmacokinetics. Pharmacogenetics and Genomics
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Introduction
The importance of understanding the role of genetics in
variation in pharmacokinetics and pharmacodynamics has
been recognized since the 1950s [1–3]. Twin studies have
historically been used to determine the heritability of
genetic diseases and traits; these studies have also been
used to determine the heritability of pharmacodynamic
and pharmacokinetic parameters [4]. Although twin
studies are a useful technique to determine genetic
contributions to pharmacokinetic variation, it can be
impractical to use twins in pharmacogenetic studies
because of the difficulty in recruitment and the need to
expose them to drugs. A statistical technique that was
specifically developed to address this issue is the
repeated drug administration (RDA) method, which uses
repeated administrations of a drug to the same individuals
to compare the within-participant and between-partici-
pant variation in pharmacokinetic parameters [5]. This
comparison can be used to quantify the relative genetic
contribution to variations in pharmacokinetic parameters
of a drug. Although the RDA method is useful in
determining whether pharmacokinetic or pharmacody-
namic parameters of a drug have strong genetic compo-
nents, it may vary with the route of administration, dose
of drug, or patient population [5]. In addition, while one
pharmacokinetic parameter for a given drug may have a
strong relative genetic component, other parameters may
be more highly influenced by environmental factors than
by genetic factors [6]. RDA has successfully been used to
characterize the genetic contribution to variability in
pharmacokinetic parameters of several drugs, including
erythromycin, midazolam, and metformin [7,8]. However,
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the genetic contribution to pharmacokinetic parameter
variability for many drugs is still unknown.
Nevirapine is a non-nucleoside reverse transcriptase
inhibitor widely used as a component of antiretroviral
therapy in the treatment of HIV [9]. Nevirapine exhibits
considerable variability in its pharmacokinetic properties;
however, only part of this variability can be explained by
environmental factors and concomitant conditions [10].
Variation in nevirapine pharmacokinetics can lead to
reduced efficacy, increased viral resistance, and increased
toxicities [11]. Nevirapine is metabolized to its primary
metabolite 3-hydroxynevirapine by CYP2B6 [12]. The
CYP2B6 516G>T and CYP2B6 983T>C variant alleles
have a significant effect on nevirapine plasma levels, and
the CYP2B6 516T allele has also been associated with
increased recovery of CD4+ T-cell populations in pedia-
tric patients following initiation of nevirapine-containing
antiretroviral therapy [13–15]. In addition, ABCB1
3435C>T has been associated with protection against
nevirapine-induced hepatotoxicity and increased nevira-
pine concentrations in cerebrospinal fluid [16,17]. De-
spite evidence that nevirapine pharmacokinetics are
influenced by specific polymorphisms, there has not been
a study conducted to quantify the relative genetic contri-
bution to variability in nevirapine pharmacokinetics.
This study uses the RDA method to quantify the relative
genetic contribution to variability in nevirapine pharma-
cokinetics. A significant relative genetic contribution to
variation in nevirapine exposure was shown in two ethnic
populations. The contribution of CYP2B6 516G>T and
ABCB1 3435C>T to variability in nevirapine pharmaco-
kinetics was also investigated.
Materials and methods
Study design and participants
Participants were recruited from the Research in Access
to Care in the Homeless cohort as previously de-
scribed [18]. Study participants are marginally housed
HIV-positive individuals living in San Francisco. Nineteen
patients were recruited to participate in a pharmacoki-
netic study where patients receiving 200mg nevirapine
twice daily consented to pharmacokinetic blood sampling.
All patients were on therapy at least 4 months and were
concomitantly receiving two nucleoside reverse transcrip-
tase inhibitors. Patients were presumed to have reached
steady state concentrations. Blood samples were drawn at
0, 1, 2, 3, and 6 h after each dose. The time between the
two measured doses varied from 13 to 173 days. European
American (n=11) and African American (n=6) patients
were included in this study. Ethnicity was self-reported
and verified through genotyping of 112 ancestry informa-
tive markers and analysis using the STRUCTURE
program [19–21]. The study was approved by the
University of California Institutional Review Board and
all participants provided written informed consent before
participation.
Nevirapine quantification
Plasma was prepared from blood samples by centrifuga-
tion and stored at – 801C until analysis. Nevirapine was
extracted using Oasis HLB SPE columns (Waters Corp.,
Milford, Massachusetts, USA) and plasma concentrations
were quantified by LC/MS/MS analysis as described by
Mistri et al. [22]. Briefly, each 0.5ml plasma aliquot was
heated for 1.5 h at 561C to inactivate HIV-1 virus and
then spiked with 25 ml of 20 mmol/l metaxolone (Toronto
Research Chemicals, Toronto, Ontario, Canada) in
methanol, which served as an internal standard. SPE
columns were equilibrated with 1ml methanol followed
by 1ml distilled water. Samples were then loaded on the
column and washed with 1ml of 2mmol/l ammonium
acetate followed by 1ml of water. Samples were eluted in
1ml mobile phase (80 : 20 acetonitrile : water, 0.1% acetic
acid) and a 5 ml aliquot was injected onto a 5 mm Hypersil
BDS C18 column, 50 4.6 mm (Thermo Fisher Scientific,
Waltham, Massachusetts, USA). The flow rate into
the API4000 mass spectrometer (AbSciex, Framingham,
Massachusetts, USA) was 0.2ml/min and nevirapine reten-
tion time was 1.7min. The parent ion (m/z 267.2 amu) and
product ion (m/z 226.2 amu) were monitored at Q1 and Q3,
respectively. Nevirapine standard curves were linear from
50 to 5000ng/ml (r2>0.9). Assay accuracy was between
100.3 and 112.9% relative SD. Assay precision ranged from
8.2 to 18.5% coefficient of variation.
Genotyping
Genomic DNA was extracted from whole blood samples.
Genotyping of polymorphisms of interest (CYP2B6
516G>T and ABCB1 3435C>T) was accomplished
using the ABI Prism 7900HT Sequence Detection System
(Applied Biosystems, Foster City, California, USA). Taq-
Man assays were used to genotype CYP2B6 516G>T
(rs3745274, Assay ID: C___7817765_60) and ABCB1
3435C>T (rs1045642, Assay ID: C___7586657_20).
Genotypes were called using the ABI Sequence Detection
System software (version 2.1; Applied Biosystems).
Calculation of pharmacokinetic parameters
Because of the long half-life of nevirapine (45 h), only
AUC0–6 h was calculated [23]. AUC0–6 h was calculated for
each dose administration using the trapezoidal rule.
Calculation of the relative genetic component
The genetic contribution to the variability in nevirapine
AUC0–6 h was assessed with a modified analysis of
variance (ANOVA) formula for estimating the relative
genetic component or rGC and 95% confidence intervals
(CIs) proposed by Kalow et al. [24]:
rGC ¼ SD2bSD2w
 
=SD2b;
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which can be rearranged as:
rGC ¼ 1 1=Fð Þ;
where F ¼ SD2b=SD2w:
Upper and lower CIs can be calculated as follows:
Lower 95% CI ¼ Fobserved=F0:025; b:d :f ;w:d :f :;
Upper 95% CI ¼ FobservedF0:025; b:d :f ;w:d :f :;
where rGC represents the estimated relative genetic com-
ponent, SDb
2 is the between-participant variation, SDw
2 is
the within-participant variation, b.d.f. is the between-
participant degrees of freedom, w.d.f. is the within-
participant degrees of freedom, and F0.025 is the tabulated
F statistic at the 2.5% significance level at the appropriate
degrees of freedom. Because of well-characterized differ-
ences in allele frequency and linkage disequilibrium
patterns, European Americans (n=11) and African Amer-
icans (n=6) were analyzed separately in this study.
Statistical methods
Statistical significance for genetic contribution to AUC0–6 h
variability was calculated using an F-test, a=0.05, to
determine whether the interindividual and intraindividual
variation was significantly different. One-way ANOVA,
a=0.05, was used to determine significance for the effect
of genetic polymorphisms on AUC0–6 h values. All other
calculations of P-values were obtained using two-sided
t tests or one-way ANOVA as appropriate [25]. Calculations
were performed using R and Microsoft Excel [26]. All
figures were produced in Prism Version 5.01 (GraphPad
Software Inc., San Diego, California, USA).
Results
Ethnicity does not play a role in nevirapine AUC0–6 h
variability
As there are well-characterized differences in the genetic
structure and linkage disequilibrium patterns in various
ethnic populations, a statistical analysis to examine any
overall differences in nevirapine AUC0–6 h between
African and European Americans was conducted. A total
of 17 participants were included in this study, 11
European Americans and six African Americans (Table 1).
Median ages and concomitant medications were similar in
the two ethnic groups, whereas the African American
group had a higher proportion of women than the
European American group.
Analysis of nevirapine plasma concentrations indicated
very little intraparticipant variability in concentrations
during the 6 h after drug administration, consistent with
the long terminal half-life of this drug (Figs 1 and 2,
Supplemental digital content, Fig. 1, http://links.lww.com/
FPC/A639). In contrast, there is considerable variation in
nevirapine concentrations between individuals; three
individuals in the African American and two in the
European American groups never reach plasma concen-
trations above the minimum effective concentration for
nevirapine of 3000mg/l [27]. Average AUC0–6h did not
differ between the two visits, although there was significant
interpatient variability in these values (Table 1). For
example, the mean AUC0–6 h was 22.5mg nevirapine/l h
(SEM=3.81mg nevirapine/l h) and 18.3mg nevirapine/l h
(SEM=2.69mg nevirapine/l h) for European and African
Americans, respectively. There was no significant differ-
ence in AUC0–6h between the two populations (t-test,
P=0.45).
Age and sex do not play a role in the variability of
nevirapine AUC0–6h
To ensure that further analyses were not confounded by
demographic factors, the effect of age and sex on
nevirapine AUC0–6 h was examined by linear regression
and t tests, respectively. Age had no effect on nevirapine
AUC0–6 h with an r
2 of 0.04. Men tended to have slightly
lower AUC0–6 h (16.2mg nevirapine/l h, SEM=37.0mg
nevirapine/l h) than women (23.0mg nevirapine/l h,
SEM=24.2mg nevirapine/l h), however this difference
was not statistically significant (P=0.14).
There is a significant genetic contribution to variation
in nevirapine AUC0–6h
The relative genetic contribution to nevirapine pharma-
cokinetics was calculated using the RDA method as
described previously [5,7]. The between-participant
(SDb
2) variation in AUC0–6 h was about 10-fold greater
than the within-participant variation (SDw
2) in both
ethnic groups (Table 1). The rGC calculated for the
European Americans and African Americans was 0.904
(95% CIs 0.64–0.97) and 0.902 (95% CIs 0.42–0.98),
respectively. F tests indicate that there is a significant
genetic contribution to the variability in AUC0–6 h in both
Europeans (P=0.02) and African Americans (P=0.01).
Table 1 Patient demographics and relative genetic contribution
(rGC) to nevirapine AUC0–6h
European Americans African Americans
Sample size (n) 11 6
Sex [n (%)]
Male 4 (36) 1 (17)
Female 7 (64) 5 (83)
Age (years)
Median 45 49
Range 29–57 33–74
Nevirapine AUC0–6h (mg/l h)
a
SDw
2 2.39 5.34
SDb
2 24.9 54.7
Estimated relative genetic component
rGC
b (95% CI) 0.904 (0.64–0.97) 0.902 (0.42–0.98)
F 10.4 10.2
P 0.02 0.01
AUC, area under the curve; CI, confidence interval.
aSDw
2 is within-individual variation and SDb
2 is within-participant variation.
bEstimated relative genetic component.
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CYP2B6 516G>T may influence nevirapine AUC0–6h
Considering the evidence for a significant genetic
contribution to the variability in nevirapine exposure,
polymorphisms in candidate genes implicated in the
metabolism and transport of nevirapine were tested for
association with nevirapine pharmacokinetics. In African
Americans, there is a trend for increased plasma
nevirapine levels in individuals carrying the CYP2B6
516G>T allele or the ABCB1 3435C>T allele (Figs 1a
and 2a); however, the sample sizes are too small for formal
statistical analysis (Table 2). A similar trend was observed
for the CYP2B6 516G>T allele in European Americans,
but these differences did not reach statistical significance
(Fig. 1b and Table 2). There was no indication of an
association between the ABCB1 3435C>T polymorph-
ism and nevirapine pharmacokinetics in European
Americans (Fig. 2b and Table 2).
Discussion
Although there have been many candidate gene studies
on nevirapine pharmacokinetics, this is the first study to
determine the overall relative genetic influence on
nevirapine pharmacokinetics. A significant relative genet-
ic contribution to the variability in nevirapine pharmaco-
kinetics was demonstrated in European and African
Americans. This supports previous findings that have
implicated polymorphisms in drug metabolism and
transport genes in nevirapine pharmacokinetic variability
and toxicity [14–16]. A trend consistent with previous
studies of elevated plasma concentrations in participants
homozygous for the CYP2B6 516G>T allele was also
observed [13,15].
Variability in nevirapine pharmacokinetics and toxicity
has been observed since its approval for the treatment of
Fig. 1
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Nevirapine plasma concentrations following a 200mg dose to (a) African Americans and (b) European Americans. The concentrations (mean±SEM)
are stratified by CYP2B6 516G>T genotype: circles: GG, squares: GT, and triangles: TT.
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Nevirapine plasma concentrations following a 200mg dose to (a) African Americans and (b) European Americans. The concentrations (mean±SEM)
are stratified by ABCB1 3435C>T genotype: circles: CC and squares: CT.
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HIV. Many candidate gene studies have confirmed that
a portion of pharmacokinetic variability is because of
polymorphisms in CYP2B6 [14,28,29]. However, the
variation in pharmacokinetics due to genetic versus
environmental factors has never been examined. The
current study demonstrates that there is a significant
genetic component to nevirapine pharmacokinetics in
African and European Americans. Although the popula-
tion examined here is small, one advantage of the RDA
method is the ability to use small populations to estimate
relative genetic components of drugs [6]. In our
European population, we have a reasonable number of
participants to estimate a 95% lower confidence limit
of B0.65 for an rGC of 0.9 [6]. This suggests that
interindividual variation in nevirapine drug levels could
be reduced through knowledge of a patient’s genetic
background. The importance of this is reflected in the
observation that several patients did not reach the
minimum effective concentration of nevirapine, which
could lead to decreased efficacy against HIV and
increased viral resistance to nevirapine. The RDA
method has been successfully used to identify drugs
whose renal clearance has a strong genetic component
and could also be used to identify antiretroviral drugs that
are good candidates for pharmacogenomics research [8].
To further investigate the influence of genetics on
nevirapine pharmacokinetics, two candidate polymorphisms
were selected for study. A trend was observed toward
elevated AUC0–6h of nevirapine in both European and
African Americans homozygous for the CYP2B6 516G>T
polymorphism. This polymorphism has been associated with
a slight decrease in hepatic protein expression and function,
therefore increases in AUC0–6 are expected [30]. Although
the results in European Americans did not reach statistical
significance, the analysis was limited by a small sample
size and may have been confounded by unidentified
environmental factors. The trend observed is consistent
with other published work, which supports the need for
a larger study population [14,15,31]. No association of
ABCB1 3435C>T with nevirapine exposure was observed
in our study. The effect of this polymorphism on nevirapine
pharmacokinetics remains controversial, with many studies
not showing an effect on nevirapine plasma pharmacoki-
netics [13–15,29,32]. AUC0–6h may not be the most appro-
priate pharmacokinetic parameter to observe the effects of
these polymorphisms; however, because of the long half-life
of nevirapine, it was not possible to calculate other pharma-
cokinetic parameters such as half-life or oral clearance.
The current study demonstrates that there is a significant
relative genetic component to nevirapine pharmacoki-
netics. Although CYP2B6 polymorphisms have been
attributed to some of this variation [14,15,31], this study
suggests that there may be additional genetic factors that
influence nevirapine pharmacokinetics. These data sup-
port additional research to discover novel genetic factors
influencing nevirapine variability. Further, the RDA
method could also be used to study endpoints of
antiretroviral drugs other than pharmacokinetic para-
meters, including pharmacodynamic and metabolomic
endpoints [33]. Additional knowledge of genetic factors
that affect nevirapine pharmacokinetics may help
increase the efficacy of nevirapine in the treatment of
HIV and lead to less viral resistance.
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